Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 plus Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
NCT04881929Phase 2Unknown
- Sponsor
- Alphamab Oncology
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab in HER2-positive breast cancer, sponsored by Alphamab Oncology. Status: unknown.
02
Drugs
anbenitamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04881929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881929.